Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Finasteride may help treat BPH by affecting certain biological markers.

This article reviews updates on 5 alpha-reductase inhibitors for treating male pattern hair loss and presents no new clinical findings; the author aims to enhance understanding of these therapies.

In this study, FCE 28260 showed greater potency than finasteride in inhibiting 5α-reductase enzymes and reducing prostate DHT levels in rats.

This study found that both a proprietary ultrahigh-pressure extract and a hexanic extract of saw palmetto showed comparable inhibition of 5α-reductase, suggesting similar potential for managing symptoms of benign prostatic hyperplasia.

This review discusses the potential uses of 5α-reductase inhibitors for conditions ranging from benign prostatic hyperplasia to skin disorders like acne and male pattern baldness, but it reports no new clinical results.

This study found that PRO 160/120 and Finasteride showed similar effectiveness in improving urinary symptoms and quality of life in patients with benign prostatic hyperplasia over 48 weeks.

This study found that compound 4 from Urtica triangularis subsp. pinnatifida exhibited stronger anti-BPH activity against BPH-1 cells with an IC50 of 79.75 μM compared to finasteride's IC50 of 91.8 μM, while compounds 1, 2, and 5 showed moderate activity.

This study found that in men with benign prostatic hyperplasia, a 3-month treatment with a long-acting GnRH agonist significantly reduced intraprostatic DHT and 3α-diol levels by about 90% and testosterone by about 75%.

This study found that Sonirid Duo, a combination of tamsulosin and finasteride, significantly improved symptoms and quality of life in patients with BPH over 12 months.

This study found that seniors using finasteride or dutasteride for benign prostatic hyperplasia may have an increased risk of depression and self-harm, especially during the first 18 months of treatment.

This study found that the synthesized compound 7b exhibited higher 5α-reductase inhibitory activity, increased solubility, and dissolution compared to finasteride, suggesting its potential as a lead compound for benign prostatic hyperplasia treatment.

This review discusses medical therapies for benign prostatic hyperplasia, highlighting the importance of personalizing treatments to individual patient needs and preferences.

Combination therapy for BPH is cost-effective, especially for men with larger prostates.

In this retrospective study, researchers found that coadministration of finasteride and sildenafil in patients with benign prostatic hyperplasia improved both lower urinary tract symptoms and sexual function, without significant changes in vital signs, after a treatment period averaging 18 weeks.

This study found that for men with moderate-to-severe LUTS/BPH, 6 months of treatment with tamsulosin plus the hexanic extract of S. repens was as effective as tamsulosin plus a 5-alpha-reductase inhibitor but had better tolerability.

In this study, treatment with a 5a-reductase inhibitor increased CD8+ T cell infiltration in benign prostatic hyperplasia tissues, suggesting an impact on inflammatory responses.

This study describes the development of microneedle array patches for finasteride that released the drug over 7 to 14 days in vitro, suggesting a potential alternative to oral treatments for long-term management of benign prostatic hyperplasia and androgenic alopecia.

This article narrates a case where a patient with androgenetic alopecia faced high out-of-pocket costs for finasteride 1 mg and sought to reduce expenses by requesting a prescription for 5 mg tablets typically used for BPH, which are covered by insurance.

This study found that Croton membranaceus root extract induced CYP1A2 and GSTM1 enzymes but inhibited CYP3A4 and CYP2D6 in rat livers, suggesting caution in its use with other drugs.

This study found that men with depression, erectile dysfunction, and marijuana usage were more likely to be treated for lower urinary tract symptoms, while alcohol use was not significantly associated.

This study found that frailty independently raises the risk of clinical BPH progression and serious adverse events in older men, suggesting that shared decision-making is essential when considering medical therapy for frail patients.

This commentary discusses the historical understanding of castration's effects on benign prostatic hyperplasia and reports no new clinical findings.

Early balding may be a sign of future prostate problems.

This study found that taking 1 mg of finasteride daily for male-pattern hair loss significantly reduces serum PSA levels, suggesting similar PSA adjustment is needed as for higher doses during prostate cancer screening.

This research concludes that finasteride significantly reduces dihydrotestosterone levels and prostate size in men with BPH and may improve urinary symptoms, with greater baseline prostate size predicting more pronounced benefits compared to placebo.

This study observed improvements in hair loss, acne, and BPH symptoms after addressing vitamin D and progesterone deficiencies in male patients, suggesting the potential benefits of this therapeutic approach.

This study reports that a new boron/nitrogen-doped carbon nano-onion-based delivery system for doxorubicin enhanced its uptake and anticancer effects in specific cancer cell types, while reducing cardiotoxicity in human heart cells.

Finasteride effectively reduces the need for surgery and urinary issues in men with BPH over the long term.

This review discusses the use of finasteride and alpha antagonists for symptomatic benign prostatic hypertrophy and suggests current studies are evaluating combination therapies as potential non-surgical alternatives.

In this study, marijuana use and depression were associated with a higher likelihood of being treated for lower urinary tract symptoms in men over 45 in a marijuana-legalized region.